Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	18.17	20.01	22.99	19.36	49.65	48.08
Cash & Short-Term Investments	18.17	20.01	22.99	19.36	49.65	48.08
Cash Growth	-8.03%	-12.96%	18.72%	-61.01%	3.26%	335.36%
Receivables	35.83	23.62	28.94	21.71	28.18	5.63
Inventory	11.06	12.63	12	10.85	16.34	10
Prepaid Expenses	7.46	5.64	7.16	7.38	9.78	5.72
Restricted Cash	-	-	-	-	0.25	0.25
Other Current Assets	-	-	-	0.63	1.04	5.74
Total Current Assets	72.51	61.89	71.08	59.93	105.23	75.42
Property, Plant & Equipment	1.66	1.52	3.87	6.3	8.7	0.89
Goodwill	-	-	-	-	65.8	28.09
Other Intangible Assets	48.71	52.45	58.97	70.63	85.46	48.86
Long-Term Deferred Tax Assets	-	0.76	1.38	-	-	-
Other Long-Term Assets	1.32	1.47	1.17	0.77	0.47	0.03
Total Assets	124.2	118.1	136.46	137.62	265.67	153.29
Accounts Payable	12.04	10.44	13.48	10.99	19.26	11.64
Accrued Expenses	41.73	22.69	25.28	25.71	30.72	10.3
Short-Term Debt	10.03	2.4	1.56	3.81	7.93	-
Current Portion of Long-Term Debt	1.86	1.86	-	-	16.57	0.98
Current Portion of Leases	-	0.71	1.34	0.1	0.1	0.3
Other Current Liabilities	5.05	24.14	27.35	23.84	34.86	5.54
Total Current Liabilities	70.71	62.23	69.02	64.44	109.44	28.76
Long-Term Debt	9.54	10.88	14.71	14.2	-	-
Long-Term Leases	-	0.58	0.83	0.08	0.18	0.73
Long-Term Deferred Tax Liabilities	-	0.76	1.38	-	-	-
Other Long-Term Liabilities	9.06	15.94	11.17	14.59	18.48	28.79
Total Liabilities	89.3	90.38	97.11	93.32	128.1	58.28
Common Stock	0	0	0	-	0	0
Additional Paid-In Capital	348.61	347.69	343.49	331.39	315.86	215.02
Retained Earnings	-313.72	-319.97	-304.13	-287.08	-178.3	-120.01
Total Common Equity	34.9	27.72	39.36	44.31	137.57	95.02
Shareholders' Equity	34.9	27.72	39.36	44.31	137.57	95.02
Total Liabilities & Equity	124.2	118.1	136.46	137.62	265.67	153.29
Total Debt	21.42	16.42	18.45	18.19	24.78	2.01
Net Cash (Debt)	-3.25	3.59	4.53	1.17	24.87	46.08
Net Cash Growth	-	-20.87%	286.86%	-95.29%	-46.03%	317.19%
Net Cash Per Share	-0.41	0.65	1.36	0.80	29.70	203.91
Filing Date Shares Outstanding	6.17	6.15	5.53	3.12	1.38	0.63
Total Common Shares Outstanding	6.17	5.97	5.52	1.93	1.37	0.63
Working Capital	1.81	-0.34	2.06	-4.51	-4.2	46.66
Book Value Per Share	5.66	4.64	7.13	22.97	100.08	151.01
Tangible Book Value	-13.81	-24.74	-19.61	-26.32	-13.7	18.07
Tangible Book Value Per Share	-2.24	-4.14	-3.55	-13.65	-9.97	28.72
Machinery	-	2.78	4.39	4.45	5	0.51
Construction In Progress	-	-	0.11	-	0.2	-
Leasehold Improvements	-	0.04	1	1	0.96	0.23

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q